Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aceon Gets Coronary Artery Disease Approval Ahead Of Schedule

This article was originally published in The Pink Sheet Daily

Executive Summary

Aceon adds indication for reduction of risk of cardiovascular mortality and non-fatal myocardial infarction in patients with stable coronary artery disease ahead of Sept. 10 user fee date.

You may also be interested in...

Ranexa NDA Amendment Seeks Restricted Angina Indication

CV Therapeutics' complete response to FDA's October 2003 "approvable" letter is based on the ERICA trial in patients refractory to the maximum labeled dose of Pfizer's calcium channel blocker Norvasc.

Aceon User Fee Deadline Extended To Allow For Clinical Trial Site Audits

Audits of European clinical trial sites have shown “more audit observations than the FDA was comfortable with,” CV Therapeutics says. The 90-day extension will allow for further audits of the EUROPA trial sites. CVT may add a product for its cardiovascular sales team to promote alongside Aceon and Ranexa.

Tarceva Pancreatic Cancer Indication Turned Down In The EU

Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts